Duchenne Muscular Dystrophy (DMD)

DMD — Halo Therapeutics

MDA awarded a $500,000 grant to biotechnology company Halo Therapeutics for development of a treatment for Duchenne muscular dystrophy (DMD). The two-year grant begins in November 2013 and will run through Nov. 15, 2014. The Newton, Mass., company is developing HT-100, an experimental compound designed to combat excessive inflammation and formation of scar tissue in muscle and promote muscle regeneration.

RE: FDA Says That New Drug Application Filing for Eteplirsen is Premature

FDA Says New Drug Application Filing for Eteplirsen is Premature

Utrophin Modulator SMT C1100 To Be Tested in DMD Patients

Summit PLC, a biotechnology company based in Abingdon, United Kingdom, has announced it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and Ethics Review Committee to begin testing its experimental drug SMT C1100 in children with Duchenne muscular dystrophy (DMD).

MDA Grant Will Help Families in DMD Steroid Study

Robert Griggs, a professor of neurology at the University of Rochester (N.Y.), has received an MDA grant of $237,316 over three years to support travel costs for North American participants in a large, multinational trial to determine which corticosteroid treatment regimen is best for children with Duchenne muscular dystrophy (DMD).

DMD — Robert Griggs, M.D.

Robert Griggs, a professor of neurology at the University of Rochester in New York state, received an MDA grant of $237,316 over three years to cover travel costs for North American participants in a clinical trial of prednisone and deflazacort, two corticosteroid drugs used to treat Duchenne muscular dystrophy (DMD).

DMD: Sarepta Updates Community on Eteplirsen Plans, Pipeline

Sarepta Therapeutics announced it is on track to submit an application to the U.S. Food and Drug Administration (FDA) for approval of eteplirsen in the first half of 2014.

In parallel with that application, the company is preparing to conduct a large-scale, confirmatory trial of eteplirsen. It plans to open the trial during the first quarter of 2014.

DMD: Companies To Host Web Presentations on Exon Skipping

Prosensa Says It Remains Committed to DMD

"Our commitment to Duchenne muscular dystrophy remains," said Hans Schikan, CEO of Netherlands-based biotechnology company Prosensa at a Sept. 27, 2013, presentation in New York.

UPDATE: DMD: Eteplirsen Shows Continued Benefit at 84 Weeks

Pages